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Purpose: Granulocyte colony stimulating factor (G-CSF) has been known to in-
crease neutrophil production and have anti-inflammatory properties, but the effect of 
G-CSF on pulmonary system is in controversy. We investigated whether G-CSF 
treatment could attenuate hyperoxia-induced lung injury, and whether this protective 
effect is mediated by the down-modulation of inflammatory responses in a neonatal 
rat model. Materials and Methods: Newborn Sprague-Dawley rats (Orient Co., 
Seoul, Korea) were subjected to 14 days of hyperoxia (90% oxygen) beginning 
within 10 h after birth. G-CSF (20 μg/kg) was administered intraperitoneally on the 
fourth, fifth, and sixth postnatal days. Results: This treatment significantly improved 
hyperoxia-induced reduction in body weight gain and lung pathology such as in-
creased mean linear intercept, mean alveolar volume, terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end labeling positive cells. Hy-
peroxia-induced activation of nicotinamide adenine dinucleotide phosphate oxidase, 
which is responsible for superoxide anion production, as evidenced by upregulation 
and membrane translocation of p67phox was significantly attenuated after G-CSF 
treatment, as were inflammatory responses such as increased myeloperoxidase activ-
ity and mRNA expression of transforming growth factor-β. However, the attenuation 
of other proinflammatory cytokines such as tumor necrosis factor-α and interleu-
kin-6 was not significant. Conclusion: In sum, G-CSF treatment significantly atten-
uated hyperoxia-induced lung injury by down-modulating the inflammatory re-
sponses in neonatal rats.
Key Words:    Granulocyte colony stimulating factor, bronchopulmonary dysplasia, 
inflammation, animals, infant, newborn
INTRODUCTION
Despite recent improvements in neonatal and perinatal medicine, bronchopulmo-
nary dysplasia (BPD) continues to represent a major cause of mortality and mor-
bidity among premature infants.1 BPD occurs in a growing premature lung, the Ga Won Jeon, et al.
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mean linear intercept (MLI) and mean alveolar volume, 
and terminal deoxynucleotidyl transferase-mediated deoxy-
uridine triphosphate nick end labeling (TUNEL) staining. 
The extent of inflammatory responses was evaluated by 
measuring myeloperoxidase (MPO) activity and mRNA 
expression of tumor necrosis factor-α (TNF-α), interleu-
kin-6 (IL-6), and transforming growth factor-β (TGF-β). 
Nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH oxidase) activation which was represented by 
membrane translocation of p67phox was measured to evalu-
ate the production of reactive oxygen species (ROS).
MATERIALS AND METHODS
Animal model
The experimental protocols described herein were reviewed 
and approved by the Animal Care and Use Committee of 
Samsung Biomedical Research Institute, Seoul, Korea. 
This study was also performed in accordance with institu-
tional and National Institutes of Health (NIH) guidelines 
for laboratory Animal Care. Timed pregnant Sprague-Daw-
ley rats (Orient Co., Seoul, Korea) were housed in individu-
al cages with free access to water and laboratory chow. Rat 
pups were delivered spontaneously and reared with their 
dams. The experiment began within 10 h after birth and 
continued through postnatal day (P) 14. 
Rat pups were randomly divided into four groups with 
six to eight animals in each group: normoxia control group 
(NC); normoxia with G-CSF treatment group (NG); hyper-
oxia control group (HC); and hyperoxia with G-CSF treat-
ment group (HG). Rat pups in the NC and NG groups were 
kept with nursing mothers in standard cages and normal 
room air throughout the experiment, and pups in the HC 
and HG groups were maintained with nursing mothers in 
standard cages within 50 L Plexiglas chambers in which an 
oxygen concentration of 90% was maintained. The humidi-
ty and environmental temperature were maintained at 50% 
and 24°C, respectively. Nursing mother rats were rotated 
daily between litters in the normoxia and hyperxoxia groups 
to avoid oxygen toxicity.
Rat pups in the NG and HG groups were injected intra-
peritoneally with 20 μg/kg of recombinant human G-CSF 
(Dong-A Pharmaceutical Co. Ltd., Seoul, Korea) in 5% 
dextrose solution (2 μg/mL) on P 4, 5 and 6. Pups in the 
NC and HC groups received the same volume of 5% dex-
trose solution injected in the same manner. The survived rat 
growth of alveoli is arrested, and the interstitium is thick-
ened, resulting in decrease of surface area for gas exchange. 
Infants with BPD are prone to respiratory tract infection, 
asthma, and respiratory decompensation, and outcome of 
growth impairment and poor neurodevelopment later in 
life.2,3 There are few effective treatments available for pre-
venting or ameliorating this common and serious disorder. 
Postnatal dexamethasone has been administered as the sole 
treatment in patients with BPD. However, it is not recom-
mended for routine use to prevent or treat BPD in preterm in-
fants because of short-term complications and long-term 
neurodevelopmental effects.4 Two phase III clinical trials for 
preventions of BPD with inhaled nitric oxide followed by 
scheduled doses of late surfactant are presently ongoing.5,6 
Therefore, the development of a new therapeutic modality to 
improve the prognosis of this disease is an urgent subject.
Although the pathogenesis of BPD has not been complete-
ly delineated, inflammatory responses mediated by neutro-
phils and proinflammatory cytokines are believed to play a 
key role in the lung injury process, leading to the develop-
ment of BPD.7 Therefore, investigation of the effectiveness 
of new therapeutic modalities with anti-inflammatory capa-
bilities in the treatment of BPD is of a great interest. 
Granulocyte colony stimulating factor (G-CSF) is a hema-
topoietic growth factor that stimulates the production and 
function of neutrophils.8 Since neutrophils are involved in tis-
sue destruction during inflammatory diseases,9 there is a con-
cern that G-CSF induced neutrophilia might aggravate in-
flammatory tissue damage. However, G-CSF has also been 
shown to have anti-inflammatory properties.10 This unique 
combination of improved production and function of neutro-
phils and anti-inflammatory effects indicates that G-CSF may 
be effective for the treatment of various inflammatory condi-
tions.11 Furthermore, G-CSF is one of the few growth factors 
that have been approved for clinical use to treat neutropenia in 
newborn infants.12 Therefore, any favorable experimental re-
sults can readily be translated into clinical practice. In the pul-
monary system, G-CSF has been shown to variously aggra-
vate,13 exhibit neutral effects on,14 or attenuate15 lung injuries. 
Overall, the available data about the role of G-CSF in the de-
velopment of lung injury remain largely controversial, and 
further studies are necessary for clarification. 
In the present study, we investigated whether G-CSF treat-
ment could attenuate hyperoxia-induced lung injury, and if 
so, whether this protective effect is mediated by down-modu-
lation of the inflammatory responses in neonatal rats. Lung 
injuries were evaluated by morphometric analyses such as G-CSF for Hyperoxic Neonatal Lung Injury
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buffer for 1 min, and then immersed in a stop/wash buffer 
and rinsed. The sections tagged with fluorescein isothiocya-
nate (FITC)-labeled anti-digoxigenin conjugate were incu-
bated at room temperature for 30 min in the dark, and   
propidium iodide (0.5 μg/mL, Sigma Co.) was used for nu-
clear counterstaining. Slides were mounted with a Vecta-
shield mounting solution (Vector Laboratories, Burlingame, 
CA, USA), and visualized by fluorescent microscopy 
(Nikon E600 fluorescence microscope, Tokyo, Japan). The 
number of TUNEL positive cells were counted in ten non-
overlapping fields with a magnifying power of ×200.
Myeloperoxidase activity
The MPO activity which is an indicator of neutrophil accu-
mulation, was made by modification of the method report-
ed by Gray, et al.18 The homogenized lung tissues in a phos-
phate buffer (pH 7.4) were centrifuged at 30,000 g for 30 
min, resuspended in another phosphate buffer with 0.5% 
hexadecyltrimethyl ammonium bromide (50 mM, pH 6.0), 
and measured absorbance changes at 460 nm, using 0.167   
mg/mL of O-dianisidine dihydrochloride and 0.0005% hy-
drogen peroxide to assay the activity of MPO. One unit of 
MPO activity equaled the amount of enzyme to degrade 1 
μmole of peroxide per minute.
Semiquantitative reverse transcriptase polymerase 
chain reaction (RT-PCR) of cytokines
The total RNA in the sample was extracted by using a RNA 
Trizol kit (Invitrogen Corporation, Carlsbad, CA, USA) ac-
cording to the manufacturer’s protocol. One microgram of 
RNA was used to produce cDNA with an Protoscript® II 
RT-PCR kit (New England Biolabs, Ipswich, MA, USA). 
PCR primers for rat TNF-α, IL-6, TGF-β and glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) were designed 
with Primer 3 (Whitehead Institute, Cambridge, MA, USA) 
and were synthesized by Bioneer Inc. (Bioneer, Daejeon, Ko-
rea). The sequence of primers used was as follows: (TNF-α) 
sense 5’-TACTGAACTTCGGGGTGATCGGTCC-3’, anti-
sense 5’-CAGCCTTGTCCCTTGAAGAGAACC-3’ (IL-
6) sense 5’-CACCAGGAACGAAAGTCAACTC-3’, anti-
sense 5’-GGAAGCATCCATCATTTCTTTG-3’ (TGF-β) 
sense 5’-CAACTGTGGAGCAACACGTAGA-3’, anti-
sense 5’-CAACCCAGGTCCTTCCTAAAGT-3’ (GAP-
DH) sense 5’-CTCTACCCACGGCAAGTTCAA-3’, anti-
sense 5’-GGGATGACCTTGCCCACAGC-3’. 
One μL of cDNA was mixed in 19 μL of reaction mixture 
of PCR Master Mix (Bioneer, Daejeon, Korea) and then 0.5 
pups in each group were weighed daily until sacrifice under 
deep pentobarbital anesthesia (60 mg/kg, intraperitoneal) at 
P 14. Morphometric and biochemical analyses of whole 
lung tissue was done.
   
Tissue preparation
For biochemical analyses, transcardiac perfusion using ice-
cold phosphate buffered saline (PBS) was done, and then 
lungs were resected, snap-frozen in liquid nitrogen, and re-
frigerated at - 80ºC.
Lungs were inflated by instillation of 10% buffered for-
malin with a constant pressure of 20 cm H2O, and fixed at 
room temperature through the night for morphometric anal-
yses. Then the fixed lung tissue was processed, and embed-
ded in paraffin. Four-micrometer-thick sections of paraffin 
blocks were stained with hematoxylin and eosin. Images of 
each field were captured using a digital camera through an 
Olympus BX40 microscope (Olympus Optical Co. Ltd., 
Tokyo, Japan).
Morphometry
MLI and mean alveolar volume were measured to evaluate 
the level of alveolarization. The mean inter-alveolar distance 
was measured as MLI, by dividing the total length of the 
lines drawn across the lung section by the number of inter-
cepts encountered, as described by Thurlbeck.16 The mean 
alveolar volume was calculated using the method reported 
by Snyder, et al.17 Briefly, a grid containing equally spaced 
crosses was placed on a uniformly enlarged photomicro-
graph of each lung field. The diameters (ℓ) of the alveoli 
containing crosses were measured along the horizontal axes 
of the crosses. The cube of the alveolar diameter times π and 
divided by 3 (ℓ3π/3) was used to estimate the mean alveolar 
volume. A minimum of two sections per rat and six fields 
per section were selected randomly and examined for each 
analysis. Analyses were carried out by two independent ob-
servers who were blind to treatment conditions. 
TUNEL staining
Immunofluorescent TUNEL staining (kit S7110 ApopTag, 
Chemicon, Temecula, CA, USA) was done to determine 
the extent of apoptosis in the lung. Deparaffinized and re-
hydrated paraffin section slides were digested for 15 min us-
ing proteinase K (20 μg/mL in PBS) (Sigma Co., St. Louis, 
MO, USA) at room temperature, washed for 10 min with 
PBS. Sections were incubated using working strength TdT 
enzyme at 37°C for 1 h after incubated using equilibration Ga Won Jeon, et al.
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antibody (1 : 1,000, DAKO, Glostrup, Denmark). Developed 
Western blots using enhanced luminol-based chemilumi-
nescent (ECL) detection reagents (Amersham Pharmacia, 
Uppsala, Sweden) were exposed to X-ray film (Fuji, To-
kyo, Japan), and re-probed with antibodies against glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) (1 : 1,000, 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA). 
The membrane fraction was presented to immunoblotting 
for calnexin (1 : 500 Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA), a membrane marker to determine the rel-
ative degree of membrane purification.
Statistical analysis
The data are expressed as mean ± SEM. Survival curve 
comparisons were performed using Kaplan-Meier analysis 
followed by a log rank test. For continuous variables with a 
normal distribution, ANOVA with a Bonferroni correction 
was performed. For variables without normal distribution, 
we performed Wilcoxon rank sum tests with Bonferroni 
corrections. p values < 0.05 were considered significant.
RESULTS
Survival rate and body weight gain
Exposure to oxygen (HC) reduced the survival rate of the an-
imals to 88% at the end of the experiment (P 14) compared 
to the 100% survival rate of the normoxia groups (NC and 
NG), and this reduced survival rate in HC was improved to 
92% with G-CSF treatment (HG), however, this improve-
μmole of each primer (Bioneer) was added for each reac-
tions which were carried out in a T1 thermocycler (Biome-
tra, Goettingen, Niedersachsen, Germany). The cycle profile 
involved was as follows: 60 s at 95°C, 60 s at X°C, where X 
is the annealing temperature for each pair of cytokine prim-
ers, and 60 s at 68°C. The PCR products were visualized by 
ethidium bromide after separated using 1.2% agarose gel 
electrophoresis. Then they were scanned by a Gel Doc 2000 
analyzer (Bio-Rad Laboratories, Hercules, CA, USA). The 
mRNA level of TNF-α, IL-6, and TGF-β were analyzed 
densitometrically with Quantity One software (Bio-Rad Lab-
oratories, Hercules, CA, USA), which were estimated from 
the density ratio of cytokines to GAPDH (control).
Western blot for p67phox membrane translocation
p67phox is a subunit of NADPH oxidase, the translocation of 
which from the cytosol to the plasma membrane generates 
reactive oxygen species (ROS) and reflects NADPH oxi-
dase activation.19 Lung tissues were fractionated into mem-
brane and cytosolic components for Western blot analysis. 
Homogenized tissues in ice-cold hypertonic solution were 
centrifuged at 600 g for 10 min, and the supernatant was 
centrifuged at 100,000 g for 1.5 h. Then the supernatant 
containing both the cytosolic and the membrane-particulate 
pellet was resuspended in hypotonic solution containing 
1% Triton X-100. Western blot analysis of these products us-
ing antibodies against the p67phox (1 : 500, BD Biosciences, 
San Diego, CA, USA), the NADPH oxidase cytosolic sub-
unit was done, and the bands were recognized by horserad-
ish-peroxidase (HRP)-conjugated anti-mouse secondary 
Fig. 1. Daily body weight gain in each experimental group. Data; mean ± SEM. NC, normoxia control group (n = 12); NG, normoxia with 
G-CSF treatment group (n = 12); HC, hyperoxia control group (n = 14); HG, hyperoxia with G-CSF treatment group (n = 14). *p < 0.05 com-
pared to NC. 
†p < 0.05 compared to HC.
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pups in the normoxia groups, indicating hyperoxia-induced 
impairments in alveolar growth, and these abnormalities 
seemed to be attenuated with G-CSF treatment (HG). Mor-
phometric data demonstrated significantly increased MLI 
and mean alveolar volume in HC compared to normoxia 
groups (NC and NG), and significant attenuation of these 
abnormalities with G-CSF treatment (HG) support these 
microscopic findings (Fig. 3). 
The numbers of TUNEL positive cells in distal lung sam-
ples were markedly increased in HC compared to the nor-
moxia groups (NC and NP), and G-CSF treatment (HG) 
ment was not statistically significant.
Although birth weight was not significantly different be-
tween the four experimental groups, body weight at P 14 in 
HC was significantly lower compared to the normoxia groups, 
and this decreased body weight gain observed in HC was sig-
nificantly improved with G-CSF treatment (HG) (Fig. 1).
Lung histopathology
Representative photomicrographs showing differences be-
tween the experimental groups are shown in Fig. 2. Fewer 
and larger alveoli were observed in HC pups compared to 
Fig. 2. Representative optical photomicrographs of P 14 rat lungs stained with hematoxylin and eosin. Scale bar = 100 µm, NC, normoxia 
control group; NG, normoxia with G-CSF treatment group; HC, hyperoxia control group; HG, hyperoxia with G-CSF treatment group.
Fig. 3. Comparisons of alveolarization measured by the mean linear intercept (A) and mean alveolar volume (B). Data; mean ± SEM. NC, 
normoxia control group (n = 6); NG, normoxia with G-CSF treatment group (n = 6); HC, hyperoxia control group (n = 8); HG, hyperoxia with 
G-CSF treatment group (n = 8). *p < 0.05 compared to NC. 
†p < 0.05 compared to HC.
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statistically significant. 
NADPH oxidase activation
When NADPH oxidase is activated, expression and mem-
brane translocation of a cytosolic subunit of NADPH oxidase 
p67phox is increased. Hyperoxia-induced production of ROS 
was evaluated by NADPH oxidase activation, because 
NADPH oxidase produces oxygen free radicals both in 
phagocytic20 and nonphagocytic cells.21 Exposure to oxygen 
(HC) significantly increased p67phox both in the cytosolic and 
membrane fractions, indicating activation of NADPH oxi-
dase, compared to the normoxia groups (NC and NG) in 
Western blot analyses, and the G-CSF (HG) significantly at-
tenuated this hyperoxia-induced NADPH oxidase activation 
(Fig. 7).
DISCUSSION
In the present study, prolonged exposure of newborn rat 
significantly attenuated this hyperoxia-induced increase in 
the number of TUNEL positive cells (Fig. 4). 
White blood cell counts and lung myeloperoxidase 
activity
Exposure to oxygen (HC and HG) significantly increased 
white blood cell counts in the blood in hyperoxia, compared 
to the normoxia groups (NC and NG), and the G-CSF in-
duced granulopoiesis was not observed at P14 (Fig. 5A).
The significantly increased MPO activity observed in HC, 
compared to the normoxia groups (NC and NG), was signifi-
cantly improved with G-CSF treatment (HG) (Fig. 5B). 
mRNA expression of TNF-α, IL-6 and TGF-β
In semi-quantitative RT-PCR, significantly increased mRNA 
levels of TNF-α, IL-6 and TGF-β were observed in HC, 
compared to the normoxia groups (NC and NG) (Fig. 6). The 
hyperoxia-induced increase in TGF-β mRNA expression was 
significantly attenuated with G-CSF treatment (HG), howev-
er, the attenuation of TNF-α and IL-6 mRNA levels was not 
Fig. 4. TUNEL positive cells (A) and number of TUNEL positive cells (B) in P14 rat lungs. TUNEL positive cells labeled with FITC (green, ar-
row) and the nuclei labeled with DAPI (blue) (Scale bar, 25 µm) (A). Data; mean ± SEM. NC, normoxia control group (n = 6); NG, normoxia 
with G-CSF treatment group (n = 6); HC, hyperoxia control group (n = 8); HG, hyperoxia with G-CSF treatment group (n = 8). *p < 0.05 com-
pared to NC. 
†p < 0.05 compared to HC. TUNEL, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end label-
ing; FITC, fluorescein isothiocyanate; DAPI, 4, 6-diamidino-2-phenylindole; G-CSF, granulocyte colony stimulating factor.
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cantly attenuated hyperoxia-induced growth retardation, 
decreased alveolarization and increased TUNEL positive 
cells in the newborn rats. 
G-CSF is clinically available for use in neonates,12 and its 
safety and feasibility have been validated in recent human 
stroke therapy trials.11 Taken together, these findings sug-
pups to hyperoxia for two weeks increased mortality, retard-
ed growth, and led to the development of lung injuries simi-
lar to those seen in premature human infants with BPD.22 
These pups exhibited decreased alveolarization, as shown 
by increased MLI and alveolar volume,23 and significantly 
increased TUNEL positive cells.24 G-CSF treatment signifi-
Fig. 6. Representative RT-PCR blots and densitometric histograms for TNF-α, IL-6, and TGF-β. NC, normoxia control group (n = 6); NG, nor-
moxia with G-CSF treatment group (n = 6); HC, hyperoxia control group (n = 6); HG, hyperoxia with G-CSF treatment group (n = 6). *p < 0.05 
compared to NC. 
†p < 0.05 compared to HC. RT-PCR, reverse transcriptase polymerase chain reaction; TNF-α, tumor necrosis factor-α; IL-
6, interleukin-6; TGF-β, transforming growth factor-β; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
Fig. 7. Western blot analysis of p67
phox in the cytosol and membrane fractions of P 14 rat lung. NC, normoxia control group (n = 6); NG, nor-
moxia with G-CSF treatment group (n = 6); HC, hyperoxia control group (n = 6); HG, hyperoxia with G-CSF treatment group (n = 6). *p < 0.05 
compared to NC. 
†p < 0.05 compared to HC.
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brane translocation of the p67phox can be served as an in 
vivo indicator of NADPH oxidase activation as shown in 
our previous study.38 
In the present study, increased expression of the p67phox 
protein was observed both in the cytosolic and membrane 
fraction in HC, and G-CSF treatment significantly attenuat-
ed hyperoxia-induced NADPH oxidase activation as evi-
denced by reduced membrane translocation of the p67phox in 
the lung tissue. As phagocytic NADPH oxidase activation 
seems to be the main source of ROS production in the lung,39 
significant attenuation of hyperoxia-induced increase in 
lung MPO activity, an indicator of the lung neutrophil accu-
mulation, with G-CSF treatment might be responsible for 
its anti-oxidative effects. 
In summary, G-CSF treatment significantly attenuated 
hyperoxia-induced lung injuries such as decreased alveolar-
ization and increased TUNEL positive cells by down-mod-
ulating the oxidative stress and inflammatory responses in 
neonatal rats. These findings suggest the potential use of G-
CSF as a new therapeutic agent for BPD. Further studies 
regarding optimal dosage, timing and safety in multi-spe-
cies preterm and term neonates will be necessary for the 
translation of the benefits of G-CSF treatment observed in 
this study to clinical trials. In addition, neurological studies 
have to be done when neonates administered with G-CSF 
neonatally become adults.　
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